MedPath

Phenytoin

Generic Name
Phenytoin
Brand Names
Dilantin, Phenytek
Drug Type
Small Molecule
Chemical Formula
C15H12N2O2
CAS Number
57-41-0
Unique Ingredient Identifier
6158TKW0C5
Background

Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.

Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects. Both parenteral and oral formulations of phenytoin are available on the market.

Indication

Phenytoin is indicated to treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery. Injectable phenytoin and Fosphenytoin, which is the phosphate ester prodrug formulation of phenytoin, are indicated to treat tonic-clonic status epilepticus, and for the prevention and treatment of seizures occurring during neurosurgery.

Associated Conditions
Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Grand Mal Status Epilepticus, Jacksonian epilepsy, Partial-Onset Seizures, Petit Mal Epilepsy, Seizure Disorder, Post Traumatic, Seizures, Status; Epilepticus, Tonic-clonic, Temporal Lobe Epilepsy (TLE), Convulsive disorders

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Phase 2
Terminated
Conditions
Sickle Cell Anemia
Hemoglobinopathy
Thalassemia
First Posted Date
2002-06-28
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
15
Registration Number
NCT00040469
Locations
🇺🇸

Texas Children's Hospital, Houston, Texas, United States

🇺🇸

The Methodist Hospital, Houston, Texas, United States

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Phase 3
Completed
Conditions
Post-Traumatic Seizure Disorder
Head Injuries
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
385
Registration Number
NCT00004817

Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis

Not Applicable
Completed
Conditions
Epilepsy
Cysticercosis
First Posted Date
1999-10-19
Last Posted Date
2015-03-25
Lead Sponsor
Johns Hopkins University
Target Recruit Count
120
Registration Number
NCT00004403

Effects of Phenytoin on Cocaine Use in Humans - 2

Phase 1
Completed
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000285
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath